Zobrazeno 1 - 1
of 1
pro vyhledávání: '"N. Roldan Ruiz"'
Autor:
N. Roldan Ruiz, C. Ramos Giráldez, C. Azabal Perez, R. Martínez, M. L. Velloso Feijoo, J. L. Marenco
Publikováno v:
Annals of the Rheumatic Diseases. 81:1336.1-1336
BackgroundUpadacitinib is the third janus kinase (JAKi) inhibitor approved for rheumatoid arthritis after baricitinib and tofacitinib. Upadacitinib is a selective JAK1 inhibitor, and is indicated for the treatment of moderate to severe active RA in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9a2d9f442bc38f1850b8899f0bc37f0
https://doi.org/10.1136/annrheumdis-2022-eular.4254
https://doi.org/10.1136/annrheumdis-2022-eular.4254
